<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="16778"><DrugName>zibotentan</DrugName><DrugNamesKey><Name id="42848863">zibotentan</Name></DrugNamesKey><DrugSynonyms><Name><Value>ZD-4054</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>zibotentan</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>AZD-4054</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-11922817</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>186497-07-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16955">Zeneca Group plc</CompanyOriginator><CompaniesPrimary><Company id="20544">University of Bristol</Company><Company id="23505">University College London</Company><Company id="20695">University of Virginia</Company></CompaniesPrimary><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company><Company id="16955">Zeneca Group plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16778" type="Drug"><TargetEntity id="258506" type="siDrug">Zibotentan</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="20544" type="Company"><TargetEntity id="4296787325" type="organizationId">University of Bristol</TargetEntity></SourceEntity><SourceEntity id="20695" type="Company"><TargetEntity id="5000886486" type="organizationId">University of Virginia</TargetEntity></SourceEntity><SourceEntity id="23505" type="Company"><TargetEntity id="4296335971" type="organizationId">University College London</TargetEntity></SourceEntity><SourceEntity id="1105" type="ciIndication"><TargetEntity id="10039710" type="MEDDRA"></TargetEntity><TargetEntity id="732" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1865" type="ciIndication"><TargetEntity id="10022562" type="MEDDRA"></TargetEntity><TargetEntity id="D007383" type="MeSH"></TargetEntity><TargetEntity id="-754677195" type="omicsDisease"></TargetEntity><TargetEntity id="261" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="770" type="Action"><TargetEntity id="141" type="Mechanism">Endothelin ETA Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00659" type="ciTarget"><TargetEntity id="44256191019093" type="siTarget">Endothelin-1 receptor</TargetEntity><TargetEntity id="-1979653943" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="1105">Scleroderma</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="1865">Intermittent claudication</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="55">Cardiac failure</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="770">Endothelin ET-A receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1615">Neuroprotectant</Action><Action id="61">Angiogenesis inhibitor</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-30T10:13:05.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>1997-12-10T18:31:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;The &lt;ulink linkID="20695" linkType="Company"&gt;University of Virginia&lt;/ulink&gt; is developing the drug for the potential treatment of intermittent claudication. In February 2014, a phase II trial was initiated in the US [&lt;ulink linkID="1455873" linkType="Reference"&gt;1455873&lt;/ulink&gt;]. &lt;ulink linkID="23505" linkType="Company"&gt;University College London&lt;/ulink&gt; (UCL),  as part of the &lt;ulink linkID="18438" linkType="Company"&gt;Medical Research Council&lt;/ulink&gt;/&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; compound collaboration,  is investigating zibotentan  (ZD-4054; AZD-4054), a   selective reversible endothelin A (ET-A) receptor antagonist, for the potential oral treatment of  scleroderma.   The &lt;ulink linkID="20544" linkType="Company"&gt;University of Bristol&lt;/ulink&gt;, also    as part of the   MRC/AZ program, is investigating the compound for the potential treatment of Alzheimer's disease [&lt;ulink linkID="1350273" linkType="Reference"&gt;1350273&lt;/ulink&gt;]. In October 2014, a phase II study was initiated in the UK, in patients with renal disease secondary to scleroderma. At that time, the study was expected to complete in April 2017 [&lt;ulink linkID="1532454" linkType="Reference"&gt;1532454&lt;/ulink&gt;]. In February 2015, development of zibotentan for Alzheimer's disease was underway [&lt;ulink linkID="1638778" linkType="Reference"&gt;1638778&lt;/ulink&gt;]. By September 2016, the drug was available for partnering with academics for preclinical and clinical development in other indications or as a research tool through AstraZeneca's Open Innovation program [&lt;ulink linkID="1804345" linkType="Reference"&gt;1804345&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; was developing zibotentan   for the potential   treatment of solid tumors, primarily hormone-refractory prostate cancer (HRPC) [&lt;ulink linkID="816181" linkType="Reference"&gt;816181&lt;/ulink&gt;]. However development was discontinued in 2011 [&lt;ulink linkID="1166129" linkType="Reference"&gt;1166129&lt;/ulink&gt;], &lt;ulink linkID="1210741" linkType="Reference"&gt;1210741&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2007, phase III trials  for metastatic HRPC were ongoing  [&lt;ulink linkID="816181" linkType="Reference"&gt;816181&lt;/ulink&gt;].  In September 2010, following the failure of the ENTHUSE M1 trial to achieve the primary endpoint , AstraZeneca reported that there were no plans for regulatory submission at that time [&lt;ulink linkID="1134332" linkType="Reference"&gt;1134332&lt;/ulink&gt;], and in February 2011, the company discontinued development of zibotentan as a monotherapy for HRPC, following negative interim results from the ENTHUSE M0 trial [&lt;ulink linkID="1166129" linkType="Reference"&gt;1166129&lt;/ulink&gt;]. In July 2011, AstraZeneca reported that a third trial (ENTHUSE 33) had also failed, with the drug in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; also providing no improvement in overall survival, and development of the drug was discontinued         [&lt;ulink linkID="1210741" linkType="Reference"&gt;1210741&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Development had also been carried out in other cancer settings. A phase II trial in non-small-cell lung cancer (NSCLC) began in August 2008 in Europe  [&lt;ulink linkID="942835" linkType="Reference"&gt;942835&lt;/ulink&gt;]. However, by October 2010, data from the trial indicated that there was no significant difference in overall survival, and  development was presumed to be discontinued [&lt;ulink linkID="1189965" linkType="Reference"&gt;1189965&lt;/ulink&gt;]. The drug had previously been under development by Zeneca as a potential therapeutic agent in heart failure [&lt;ulink linkID="271856" linkType="Reference"&gt;271856&lt;/ulink&gt;]; however, development for this indication had been discontinued by December 1999 [&lt;ulink linkID="349551" linkType="Reference"&gt;349551&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2010, dependent on positive data from the ENTHUSE M1 trial, a first regulatory filing in prostate had been expected in 2011 [&lt;ulink linkID="1123654" linkType="Reference"&gt;1123654&lt;/ulink&gt;]. However in September 2010, AstraZeneca reported that there were no plans for regulatory submission at that time, as the study failed to achieve the primary endpoint of significant improvement in overall survival [&lt;ulink linkID="1134332" linkType="Reference"&gt;1134332&lt;/ulink&gt;]. In January 2011, the drug had been slated for EU and US filings in 1H12 [&lt;ulink linkID="1163940" linkType="Reference"&gt;1163940&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Intermittent claudication&lt;/subtitle&gt;In June 2013, a randomized, double-blind, parallel-assigned, phase II trial (&lt;ulink linkID="143671" linkType="Protocol"&gt;NCT01890135&lt;/ulink&gt;; 1 UH3TR000959-01) to assess the safety and efficacy of zibotentan on exercise induced calf muscle perfusion was planned to be initiated in patients (n = 44) with intermittent claudication in the US. At that time, the trial was expected to complete in June 2015; in February 2014, the trial was initiated in the US [&lt;ulink linkID="1455873" linkType="Reference"&gt;1455873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2008, a randomized, double-blind, placebo-controlled, phase III multinational study (&lt;ulink linkID="40957" linkType="Protocol"&gt;NCT00626548&lt;/ulink&gt;; D4320C00015; ENTHUSE M0; Study 15) was initiated, to evaluate the safety and efficacy of zibotentan in HRPC. Patients (expected n = 1500) were to receive zibotentan or placebo in addition to standard prostate cancer therapy. The primary endpoint was overall survival. The secondary endpoints included progression free survival (PFS) and health-related quality of life. The study was expected to be completed in May 2013 [&lt;ulink linkID="1126928" linkType="Reference"&gt;1126928&lt;/ulink&gt;]. In February 2011, the study was halted after interim data showed that the trial was unlikely to meet its primary efficacy endpoint of progression free- and overall-survival; no patients completed the treatment period [&lt;ulink linkID="1166129" linkType="Reference"&gt;1166129&lt;/ulink&gt;], [&lt;ulink linkID="1126928" linkType="Reference"&gt;1126928&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2008, a randomized, double-blind, placebo-controlled, phase III study (&lt;ulink linkID="41186" linkType="Protocol"&gt;NCT00617669&lt;/ulink&gt;; D4320C00033; ENTHUSE M1C; Study 33) was initiated in the US, Argentina, Australia, Brazil, Europe, Canada, Chile, China, Colombia, India, Israel, Japan, South Korea, Mexico, Peru, Russia, South Africa and Taiwan, to evaluate the safety and efficacy of zibotentan in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in patients with metastatic HRPC. Patients (n = 1445) were to receive zibotentan (10 mg once daily) in combination with docetaxel, or placebo plus docetaxel. The primary endpoint was overall survival up to 40 months. The secondary endpoints included progression free survival and incidence of skeletal related events. The study was expected to be completed in April 2012. By July 2010, recruitment had been completed [&lt;ulink linkID="1126930" linkType="Reference"&gt;1126930&lt;/ulink&gt;], [&lt;ulink linkID="1123654" linkType="Reference"&gt;1123654&lt;/ulink&gt;], [&lt;ulink linkID="1186918" linkType="Reference"&gt;1186918&lt;/ulink&gt;]. In July 2011, initial results showed no improvement in overall survival; subsequently, the trial was discontinued [&lt;ulink linkID="1210741" linkType="Reference"&gt;1210741&lt;/ulink&gt;]. A total of 94 patients completed the  zibotentan + docetaxel arm, and 77 completed the placebo + docetaxel arm. Overall survival was  20 and 19.2 months in these groups, respectively. PFS was 7 and 7.9 months, and  skeletal-related events occurred in 17.4 and 17.3% of patients, respectively [&lt;ulink linkID="1126930" linkType="Reference"&gt;1126930&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2007, a randomized, double blind, placebo controlled, phase III study (&lt;ulink linkID="43514" linkType="Protocol"&gt;NCT00554229&lt;/ulink&gt;; D4320C00014; ENTHUSE M1; Study 14) was initiated in the US, Argentina, Australia, Brazil, Europe, Canada, China, India, Japan,  South Korea, Mexico, Russia, Singapore, South Africa and     Taiwan, to evaluate the safety and efficacy of zibotentan in patients with HRPC and bone metastases. Patients (n = 580) were to receive zibotentan or placebo in addition to standard prostate cancer therapy. The primary endpoint was overall survival (OS). The secondary endpoint included progression free survival and bone metastases formation. The study was expected to be completed in August 2010. By July 2010, recruitment had been completed [&lt;ulink linkID="1126916" linkType="Reference"&gt;1126916&lt;/ulink&gt;], [&lt;ulink linkID="1123654" linkType="Reference"&gt;1123654&lt;/ulink&gt;]. In September 2010, AstraZeneca reported that the 594-patient study did not achieve the primary endpoint of significant improvement in OS. A total of  299 patients were enrolled in the zibotentan group, and 297 in the placebo group. Overall survival was 24.5 and 22.5 months, respectively. PFS was 6.2 and 6.5 months, and time to opiate use was 16.7 and 14.8 months, respectively [&lt;ulink linkID="1134332" linkType="Reference"&gt;1134332&lt;/ulink&gt;], [&lt;ulink linkID="1126916" linkType="Reference"&gt;1126916&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In  May 2005, phase IIa data were presented at the 41st ASCO meeting in Orlando, FL. Zibotentan was administered po, once daily, to 16 patients with androgen-independent HRPC. A 10 mg/day starting dose (n = 3) was increased to 15 mg/day (n = 9), and subsequently escalated to 22.5 mg/day (n = 4). Zibotentan was found to be well tolerated at the 10 and 15 mg/day doses, with dose-limiting toxicities observed at 22.5 mg/day: one patient had grade 3 dyspnea and peripheral edema, whereas another developed grade 3 headache and intraventricular hemorrhage. The maximum-tolerated dose  was identified as 15 mg/day; most frequent adverse effects seen with this dose included headache, peripheral edema, fatigue, nasal congestion and nausea. At that time trials with 10 and 15 mg/day doses in metastatic HRPC were ongoing [&lt;ulink linkID="601283" linkType="Reference"&gt;601283&lt;/ulink&gt;], [&lt;ulink linkID="603531" linkType="Reference"&gt;603531&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2004, a randomized, double-blind, placebo-controlled, multicenter, parallel phase II study (D4320C00006; Trial 6; EPOC; formerly &lt;ulink linkID="28570" linkType="Protocol"&gt;NCT00090363&lt;/ulink&gt;, now &lt;ulink linkID="28570" linkType="Protocol"&gt;NCT00107146&lt;/ulink&gt;) began in patients with  prostate cancer and bone metastases accompanied by rising serum prostate specific antigen (PSA). Up to 270 patients were to be placed in one of three treatment arms: arm one was to receive oral zibotentan once daily, arm two was to undergo the same procedure with a slightly higher dose, and the third arm was to receive placebo. Treatment was to continue for up to 2 years in the absence of disease progression [&lt;ulink linkID="653988" linkType="Reference"&gt;653988&lt;/ulink&gt;],  [&lt;ulink linkID="653981" linkType="Reference"&gt;653981&lt;/ulink&gt;]. In September 2007, data were presented at the 14th European Congress of Clinical Oncology in Barcelona, Spain. The drug did not meet the primary endpoint of increased PFS, but overall survival was increased. The randomized EPOC trial compared once-daily doses of 10 or 15 mg of the drug with placebo in 312 patients. OS was 24.5 and 23.5 months for 10 and 15 mg of ZD-4054, compared with 17.3 months for placebo. Adverse events included headache, edema and nasal congestion [&lt;ulink linkID="833155" linkType="Reference"&gt;833155&lt;/ulink&gt;]. In November 2009, further data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. No significant differences were seen in the median time-to-progression for 10 or 15 mg/kg of zibotentan compared with placebo, and no correlation was observed between baseline levels of apoptosis markers and PSA [&lt;ulink linkID="1059706" linkType="Reference"&gt;1059706&lt;/ulink&gt;]. In February 2013, data were presented at the Genitourinary Cancers Symposium in Orlando, FL, showing that higher pretreatment serum CA IX possibly identified a cohort of patients more sensitive to zibotentan treatment, and higher serum TIMP-1possibly identified patients at risk for reduced OS.  [&lt;ulink linkID="1384267" linkType="Reference"&gt;1384267&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II trials in hormone-resistant prostate cancer were initiated in November 2002 [&lt;ulink linkID="469329" linkType="Reference"&gt;469329&lt;/ulink&gt;], [&lt;ulink linkID="469322" linkType="Reference"&gt;469322&lt;/ulink&gt;], [&lt;ulink linkID="469330" linkType="Reference"&gt;469330&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In August 2008, a phase II, double-blind, placebo-controlled, randomized trial (&lt;ulink linkID="28199" linkType="Protocol"&gt;NCT00745875&lt;/ulink&gt;; D4320C00035) began which would compare zibotentan to &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt; in NSCLC patients (expected n = 64) in Bulgaria, the Czech Republic, France, Romania and Ukraine. Patients would receive either ZD-4054 (10 mg oral tablet, qd) or placebo plus pemetrexed (500 mg/m2 iv infusion), with the primary outcome measure of time to death on the combination compared to pemetrexed alone. The trial was expected to be completed in August 2010 [&lt;ulink linkID="942835" linkType="Reference"&gt;942835&lt;/ulink&gt;]. In October 2010, data from the trial were published. There was no significant difference in overall survival seen between the zibotentan and placebo treatment groups [&lt;ulink linkID="1189965" linkType="Reference"&gt;1189965&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2014, a single center, randomized, placebo-controlled, three-part  phase II trial (&lt;ulink linkID="172699" linkType="Protocol"&gt;NCT02047708&lt;/ulink&gt;; 2013-003200-39; ZEBRA) was planned to be initiated in the UK in patients (n = 72) with renal disease secondary to scleroderma to evaluate the safety, tolerability and efficacy of zibotentan; in October 2014, the study was initiated. At that time, the study was expected to complete in April 2017 [&lt;ulink linkID="1532454" linkType="Reference"&gt;1532454&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2005, phase II trials in solid tumors were ongoing [&lt;ulink linkID="582814" linkType="Reference"&gt;582814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2010, data from two open-label, cross-over, randomized, phase I trials, conducted to assess the pharmacokinetics of zibotentan in healthy volunteers under fed and fasted conditions, were presented at the 101st AACR meeting in Washington DC. In the first study (4054IL/0013), 18 male subjects (n = 9 (fed), n = 9 (fasted)) aged &amp;gt;65 years received a 25 mg dose of zibotentan AUC values of 15100 and 14900 ng h/ml, Tmax values ranging from 2 to 6 and 1 to 4 h, and Cmax values of 1000 and 1270 ng/ml were seen in fed and fasted subjects, respectively. In the second study (D4320C00028), 60 male subjects (n = 30 (fed), n = 30 (fasted)) aged &amp;lt;/= 65 years received 10 mg of zibotentan. AUC values of 4030 and 4710 ng h/ml, Tmax values ranging from 1 to 6 and 0.75 to 6 h, and Cmax values of 357 and 420 ng/ml were seen in fed and fasted subjects, respectively. The drug was safe and well tolerated in both studies with headache being the most common adverse event [&lt;ulink linkID="1089875" linkType="Reference"&gt;1089875&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, an open-label, non-randomized, single-arm, single-group assigned, phase I trial (&lt;ulink linkID="193715" linkType="Protocol"&gt;NCT00997945&lt;/ulink&gt;; D4320C00041) to evaluate the single and multiple dose pharmacokinetics of ZD-4054 in male elderly Chinese patients (n = 15) with advanced solid malignancies in China. In April 2011, the trial was completed [&lt;ulink linkID="1565992" linkType="Reference"&gt;1565992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, a phase I study (&lt;ulink linkID="21071" linkType="Protocol"&gt;NCT00672581&lt;/ulink&gt;; D4320C00025; 4054IL/0025) was initiated, to assess the pharmacokinetics, safety and tolerability of zipotentan (10 mg po) in subjects (n = 32) with hepatic impairment or normal hepatic function. In March 2009, the study was completed [&lt;ulink linkID="1094426" linkType="Reference"&gt;1094426&lt;/ulink&gt;]. In April 2010, data from the trial were presented at the 101st AACR meeting in Washington DC. When compared with the normal function group,   Cmax and CL/F  were  lower in subjects with  hepatic impairment;  AUC values were  higher. Zibotentan was well tolerated, with headache  being the most common adverse event [&lt;ulink linkID="1089884" linkType="Reference"&gt;1089884&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2008, a clinical trial (to be conducted by the CRO ICON Clinical) was approved in Korea  [&lt;ulink linkID="966449" linkType="Reference"&gt;966449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2005, six phase I studies had been completed in nearly 140 volunteers [&lt;ulink linkID="637149" linkType="Reference"&gt;637149&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, clinical data were presented at the 96th AACR meeting in Anaheim, CA. A single dose, placebo-controlled, double-blind, randomized study in eight healthy male volunteers assessed whether zibotentan (10 and 30 mg, compared with placebo, with greater than 7 days between doses) could effectively block the vasoconstrictive activity of endothelin-1 (ET-1; given by brachial artery infusion). A 2 h brachial artery infusion of ET-1 (2.5 pmol/min) was commenced 2 h post-dosing with zibotentan or placebo, and the degree of forearm vasoconstriction measured between 90 and 120 min of infusion, then compared between dose groups. Forearm blood flow was reduced by 39.5% in response to brachial artery infusion of ET-1. Following administration of zibotentan (10 and 30 mg), vasoconstriction was reduced by 13.8 and 63% in the respective dose groups, relative to placebo (P vs placebo = 0.10 and 0.0125, respectively) [&lt;ulink linkID="596406" linkType="Reference"&gt;596406&lt;/ulink&gt;], [&lt;ulink linkID="597307" linkType="Reference"&gt;597307&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2004, phase I data were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. ET-1 concentrations were measured to determine the specificity of the compound for the ETA receptor. The randomized, ascending, double-blind, placebo-controlled trial enrolled 8 patients for each dose level (2.5, 10, 20, 30, 60, 120, 150 and 240 mg/kg); 2 patients in each group received placebo only. Samples were collected 4 and 24 h post dose. Evidence showed the compound to specifically antagonize ETA, with no evidence of ETB inhibition [&lt;ulink linkID="561972" linkType="Reference"&gt;561972&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AstraZeneca initiated phase I studies in healthy volunteers in May 2002. These were completed by November 2002, confirming specificity and tolerability. At that time, phase II studies in prostate cancer were in the process of being initiated and translational work in other tumors was ongoing [&lt;ulink linkID="469330" linkType="Reference"&gt;469330&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By August 2014, zibotentan (either 10 mg/kg/day, ip or 50 mg/kg/day, po) had been found to inhibit tumor cell proliferation and mortality, in murine tumor xenograft models of prostate, ovarian, breast, and other cancers.  Zibotentan 25 and 50 mg/kg/day, po also inhibited blood vessel growth [&lt;ulink linkID="1586754" linkType="Reference"&gt;1586754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, preclinical data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. Zibotentan was compared with another ET-A receptor antagonist, &lt;ulink linkID="2667" linkType="Drug"&gt;BQ-123&lt;/ulink&gt; in vitro. ET-1 induced growth of cancer cells and colorectal fibroblasts was significantly reduced more by zibotentan than BQ-123;  zibotentan also  attenuated the  levels of  expression of proteins (CTGF, collagen XI) in fibroblasts. Both compounds equally decreased ET-1 induced migration of colorectal fibroblasts [&lt;ulink linkID="1058723" linkType="Reference"&gt;1058723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA.  The drug was compared in vitro with &lt;ulink linkID="12151" linkType="Drug"&gt;atrasentan&lt;/ulink&gt;,  another endothelin ET-A antagonist, that also shows affinity for ET-B.  It was concluded that this might translate into different clinical therapeutic profiles for the two drugs [&lt;ulink linkID="844732" linkType="Reference"&gt;844732&lt;/ulink&gt;].   The impact of zibotentan alone or with &lt;ulink linkID="2944" linkType="Drug"&gt;pamidronate&lt;/ulink&gt; on the formation of soft-tissue metastases was evaluated in a mouse bladder cancer xenograft model.  Zibotentan alone caused a reduction in metastases, and in  combination  with pamidronate completely abrogated metastasis [&lt;ulink linkID="842025" linkType="Reference"&gt;842025&lt;/ulink&gt;]. Further results were presented on the impact of the drug on tumor blood supply, invasion and bone tissue. The development of blood vessels in an intradermal nude mouse xenograft model was inhibited at doses of 25 or 50 mg/kg po. In A673 cells, zibotentan failed to induce apoptosis, which confirmed its specificity for the ET-A receptor. The drug inhibited ET-1 induced actin reorganization and stress fiber formation and   dose-dependently inhibited phosphorylation of MAPK   [&lt;ulink linkID="842016" linkType="Reference"&gt;842016&lt;/ulink&gt;]. Further data, presented by researchers from the University of Munster, showed that zibotentan significantly reduced endothelin axis expression in three different human breast cancer cell lines and reduced the migration and invasion of breast cancer cells in a concentration-dependent manner. Additive anti-invasion and significant anti-migration effects were observed in combination with &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt;,  in vitro [&lt;ulink linkID="842011" linkType="Reference"&gt;842011&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2006, preclinical data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. A combination of zibotentan and the bisphosphonate, &lt;ulink linkID="2944" linkType="Drug"&gt;pamidronate&lt;/ulink&gt;, was tested in a model of bone cancer metastases in an effort to inhibit both osteoblastic and osteoclastic mechanisms.  No bone metastases were seen in  mice treated with the combination to the end of the 6-week period, and the combination was concluded clinically relevant in prostate cancer which typically forms osteoblastic bone metastases [&lt;ulink linkID="738639" linkType="Reference"&gt;738639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, data were presented at the 97th AACR meeting in Washington DC. In HEY and OVCA 433 ovarian carcinoma cell lines, zibotentan (1 microM) reduced ET-1-induced EGFR transactivation; &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; (1 microM) significantly inhibited EGF- and ET-1-induced p-EGFR, but only partially reduced the ET-1-induced p-MAPK. When zibotentan was combined with gefitinib there was complete inhibition of EGFR and MAPK phosphorylation. Zibotentan (1 microM) also inhibited cell proliferation and VEGF secretion, and  induced apoptosis; the combination therapy caused a significant reduction in cell proliferation (65%) and VEGF production (50%), and 2-fold increase in apoptosis. In a HEY ovarian carcinoma xenograft model in athymic mice, zibotentan inhibited tumor growth at  doses ranging from 10 to 50 mg/kg/day ip for 3 weeks. Zibotentan (10 mg/kg/day ip) in combination with gefitinib (125 mg/kg/day po) for 3 weeks resulted in a  partial (90%) or complete tumor regression with no significant side effects [&lt;ulink linkID="659027" linkType="Reference"&gt;659027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data were presented at the 96th AACR meeting in Anaheim, CA. Zibotentan inhibited cell proliferation, reduced vascular endothelial growth factor (VEGF) by 35% and enhanced &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; -induced apoptosis in HEY and OVCA 433 cell lines. The drug was efficacious at inhibiting the growth of HEY xenografts at doses ranging from 10 to 50 mg/kg/day ip, administered for 3 weeks. Similar inhibition of tumor growth was seen with zibotentan (25 mg/kg/day ip for 21 days) compared with paclitaxel (20 mg/kg iv 3 doses every 4 days), with a reduction of 65% compared to control [&lt;ulink linkID="597920" linkType="Reference"&gt;597920&lt;/ulink&gt;]. Similar effects were noted in combination with &lt;ulink linkID="11603" linkType="Drug"&gt;gefitinib&lt;/ulink&gt; [&lt;ulink linkID="662653" linkType="Reference"&gt;662653&lt;/ulink&gt;]. In murine osteoblast cells zibotentan was found to inhibit the ETA-mediated process. In human immature pre-osteoblast HCB-171 cells ET-1-stimulation was blocked by zibotentan [&lt;ulink linkID="594412" linkType="Reference"&gt;594412&lt;/ulink&gt;]. Proliferation of human immature pre-osteoblast HCB-171 cells was stimulated by ET-1; this was inhibited by both BQ123 and zibotentan [&lt;ulink linkID="594491" linkType="Reference"&gt;594491&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2004, data were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. Human (VLTR16) and rat (A10) epithelial cell lines were used to display the compounds inhibition of ETZ-mediated anti-apoptotic events while allowing pro-apoptotic signalling via ETB. Zibotentan displayed an IC50 value of 21 nM to ETA, but no IC50 value for ETB [&lt;ulink linkID="561975" linkType="Reference"&gt;561975&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, preclinical data were presented at the 14th EORTC-NCI-AACR meeting in Frankfurt, Germany. Zibotentan proved active at 0.03 mg/kg iv in the anesthetized dog, with a dose of 0.1 mg/kg being active for at least 7 h. Selective endothelin B agonist-induced vasodilation was not inhibited by zibotentan at a dose of 1.0 mg/kg. The orally absorbed compound     displayed good bioavailability in the rat and dog (&amp;gt; 70%) as well as a favorable toxicity profile. A single oral dose of 2 g/kg was well tolerated in the rat [&lt;ulink linkID="471274" linkType="Reference"&gt;471274&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;AstraZeneca has stated that the compound is orally bioavailable with the potential for chronic dosing. The company believes the compound has the potential to inhibit prostate tumor cell proliferation, promote tumor apoptosis, inhibit osteoblast proliferation and, at the same time, reduce pain [&lt;ulink linkID="469330" linkType="Reference"&gt;469330&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20695">University of Virginia</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1865">Intermittent claudication</Indication><StatusDate>2014-02-11T00:00:00.000Z</StatusDate><Source id="1455873" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23505">University College London</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate>2012-12-12T00:00:00.000Z</StatusDate><Source id="1350273" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2012-12-12T00:00:00.000Z</StatusDate><Source id="1350273" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2010-10-05T00:00:00.000Z</StatusDate><Source id="1189965" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="55">Cardiac failure</Indication><StatusDate>2000-01-06T00:00:00.000Z</StatusDate><Source id="349551" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210741" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2008-08-31T00:00:00.000Z</StatusDate><Source id="942835" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20695">University of Virginia</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1865">Intermittent claudication</Indication><StatusDate>2013-06-26T00:00:00.000Z</StatusDate><Source id="1455873" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-10-28T00:00:00.000Z</StatusDate><Source id="1565992" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16955">Zeneca Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>1997-12-10T18:31:24.000Z</StatusDate><Source id="271856" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2002-11-07T00:00:00.000Z</StatusDate><Source id="469330" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2004-08-25T00:00:00.000Z</StatusDate><Source id="653988" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2004-08-25T00:00:00.000Z</StatusDate><Source id="653988" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2004-08-25T00:00:00.000Z</StatusDate><Source id="653988" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2004-08-25T00:00:00.000Z</StatusDate><Source id="653988" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2004-08-25T00:00:00.000Z</StatusDate><Source id="653988" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2008-01-31T00:00:00.000Z</StatusDate><Source id="966449" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16955">Zeneca Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2000-01-06T00:00:00.000Z</StatusDate><Source id="349551" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1126930" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1041358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2004-12-01T00:00:00.000Z</StatusDate><Source id="594874" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2005-01-27T00:00:00.000Z</StatusDate><Source id="582814" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00659"><Name>Endothelin ET-A receptor</Name><SwissprotNumbers><Swissprot>P21450</Swissprot><Swissprot>P25101</Swissprot><Swissprot>P26684</Swissprot><Swissprot>Q29010</Swissprot><Swissprot>Q5KSU9</Swissprot><Swissprot>Q61614</Swissprot><Swissprot>Q95L55</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18438">Medical Research Council</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20695">University of Virginia</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1cnc(c(n1)OC)NS(=O)(=O)c2cccnc2c3ccc(cc3)c4nnco4</Smiles></StructureSmiles><Deals><Deal id="142408" title="MRC and AstraZeneca to provide funding and access to drugs for various diseases"/><Deal id="146156" title="NIH to award University of Virginia funding to develop zibotentan for intermittent claudication"/></Deals><PatentFamilies><PatentFamily id="1146548" number="WO-2009024820" title="Therapeutic treatment 014"/><PatentFamily id="1535377" number="WO-2004032922" title="5-HT 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist"/><PatentFamily id="1808903" number="WO-2006056760" title="A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer"/><PatentFamily id="1838177" number="WO-2004018044" title="Therapeutic use"/><PatentFamily id="1857545" number="WO-2009047565" title="Composition 064"/><PatentFamily id="1971567" number="WO-2009068906" title="Combinations comprising ZD-4054 and an SRC family kinase inhibitor 172"/><PatentFamily id="2049137" number="WO-2005080403" title="Chemical process"/><PatentFamily id="208706" number="WO-2004035057" title="Therapeutic treatment"/><PatentFamily id="263885" number="WO-09840332" title="Process For The Manufacture Of Arylsulfonyl Chloride"/><PatentFamily id="30841" number="WO-2005023264" title="Combination comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an LHRH  analogue and/or a bisphosphonate"/><PatentFamily id="640510" number="WO-2010004337" title="Combinations comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed"/><PatentFamily id="650022" number="WO-2007010235" title="Ethanolamine salt of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazole-2-yl] phenyl)pyridine-3-sulphonamide"/><PatentFamily id="942768" number="WO-09640681" title="N-Heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Uni-Charm Corp" id="1005954"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>